Abstract
No information is available on the use of carmustine during breastfeeding. Most sources consider breastfeeding to be contraindicated during maternal antineoplastic drug therapy, especially alkylating agents such as carmustine.[1] The manufacturer recommends that breastfeeding be discontinued during carmustine therapy and for 1 month after the last dose.
摘要
关于卡莫司汀在母乳喂养期间的使用尚无可用信息。大多数资料认为，在母亲接受抗肿瘤药物治疗期间，尤其是使用卡莫司汀等烷化剂时，母乳喂养是禁忌的。[1]制造商建议在卡莫司汀治疗期间及最后一剂后1个月内停止母乳喂养。
相似文献
5
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.卡莫司汀植入剂与替莫唑胺治疗新诊断的高级别胶质瘤的有效性和成本效益：一项系统评价与经济学评估
Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450.
8
Pharmacokinetics of nitrosoureas: comparison of 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) after oral and intravenous administration to rats.亚硝基脲类药物的药代动力学：大鼠口服和静脉注射1,3-双（2-氯乙基）-1-亚硝基脲（卡莫司汀，BCNU）和1-（2-氯乙基）-3-环己基-1-亚硝基脲（洛莫司汀，CCNU）后的比较
Tumori. 1984 Dec 31;70(6):499-502. doi: 10.1177/030089168407000605.
10
Mechanism of action of (2-haloethyl)nitrosoureas on DNA. Isolation and reactions of postulated 2-(alkylimino)-3-nitrosooxazolidine intermediates in the decomposition of 1,3-bis(2-chloroethyl)-, 1-(2-chloroethyl)-3-cyclohexyl-, and 1-(2-chloroethyl)-3-(4'-trans-methylcyclohexyl)-1-nitrosourea.（2-卤代乙基）亚硝基脲对DNA的作用机制。1,3-双（2-氯乙基）-、1-（2-氯乙基）-3-环己基-和1-（2-氯乙基）-3-（4'-反式甲基环己基）-1-亚硝基脲分解过程中假定的2-（烷基亚氨基）-3-亚硝基恶唑烷中间体的分离与反应。
J Med Chem. 1981 Mar;24(3):270-9. doi: 10.1021/jm00135a007.
Zotero 插件